Table 3. PRs of Subgroup Differences in Patients Who Had All (vs. Less Than All) Viral Loads Suppressed During 12 Months of Observation, 2012–2013*.
| Subgroups | Univariate PR and 95% Confidence Interval | Multivariable† PR and 95% Confidence Interval |
|---|---|---|
| Sex‡ | ||
| Female | Ref | Ref |
| Male | 1.12 (1.08 to 1.15)§ | 1.05 (1.02 to 1.09)§ |
| Age at the time of entry in cohort, yr | ||
| 18–39 | Ref | Ref |
| 40–49 | 1.24 (1.18 to 1.30)§ | 1.22 (1.17 to 1.28)§ |
| 50–91 | 1.36 (1.31 to 1.43)§ | 1.35 (1.29 to 1.40)§ |
| Race/ethnicity | ||
| White non-Hispanic | Ref | Ref |
| Black non-Hispanic | 0.89 (0.86 to 0.92)§ | 0.96 (0.93 to 0.99)‖ |
| Hispanic | 1.01 (0.97 to 1.05) | 1.12 (1.08 to 1.15)§ |
| Other | 1.04 (0.97 to 1.13) | 1.07 (1.01 to 1.15) ‖ |
| HIV acquisition (exposure) risk category | ||
| Heterosexual | Ref | Ref |
| MSM | 1.13 (1.09 to 1.16)§ | 0.98 (0.95 to 1.02) |
| MSM + IDU | 1.02 (0.96 to 1.09) | 0.88 (0.83 to 0.94)§ |
| IDU | 0.99 (0.93 to 1.06) | 0.95 (0.90 to 1.01) |
| Undetermined/unknown/other/missing¶ | 0.99 (0.94 to 1.06) | 1.03 (0.97 to 1.10) |
| Recency of testing HIV positive (from the time of entry viral load), mo | ||
| <3 | Ref | Ref |
| 3–12 | 1.04 (0.92 to 1.18) | 1.18 (1.04 to 1.33)§ |
| 13–24 | 1.57 (1.45 to 1.72)§ | 1.59 (1.47 to 1.73)§ |
| 25–48 | 1.46 (1.35 to 1.58)§ | 1.44 (1.34 to 1.56)§ |
| 49+ | 1.52 (1.42 to 1.63)§ | 1.38 (1.29 to 1.47)§ |
| No. viral load results during observation | ||
| 2 | Ref | Ref |
| 3 | 1.03 (0.99 to 1.06) | 1.02 (0.99 to 1.05) |
| 4 | 0.91 (0.87 to 0.94)§ | 0.93 (0.90 to 0.97)§ |
| 5 | 0.66 (0.62 to 0.71)§ | 0.76 (0.71 to 0.81)§ |
| 6–10 | 0.42 (0.37 to 0.47)§ | 0.55 (0.49 to 0.61)§ |
| Missed scheduled HIV primary care visit# | ||
| 0 | Ref | Ref |
| 1 | 0.78 (0.76 to 0.82)§ | 0.85 (0.82 to 0.88)§ |
| 2 | 0.59 (0.54 to 0.65)§ | 0.70 (0.65 to 0.77)§ |
| 3+ | 0.33 (0.24 to 0.45)§ | 0.48 (0.36 to 0.65)§ |
| CD4 count at the time of entry in cohort, (cells/μL) | ||
| <200 | Ref | Ref |
| 200–500 | 2.15 (1.98 to 2.33)§ | 1.89 (1.74 to 2.04)§ |
| >500 | 2.67 (2.46 to 2.89)§ | 2.26 (2.10 to 2.45)§ |
| Clinic | ||
| A | Ref | Ref |
| B | 1.32 (1.24 to 1.41)§ | 1.42 (1.33 to 1.51)§ |
| C | 1.37 (1.29 to 1.45)§ | 1.27 (1.20 to 1.35)§ |
| D | 1.39 (1.31 to 1.47)§ | 1.43 (1.35 to 1.51)§ |
| E | 1.35 (1.27 to 1.44)§ | 1.28 (1.21 to 1.36)§ |
| F | 1.12 (1.06 to 1.18)§ | 1.11 (1.05 to 1.18)§ |
*
Cohort patients had at least 2 viral load tests during 12 months of observation.
†
The multivariable model (n = 10,820) included all variables listed in the table.
‡
The 69 transgender patients were not included as a separate subgroup because of small numbers, and they were not included in the denominators of the other stratification variables in this table.
§
P < 0.01.
‖
P < 0.05.
¶
The HIV acquisition (exposure) variable included 170 cases of missing data.
#
No-show without prior cancellation during 12-month observation period.